Pharming Group N.V. announces that it has received a positive decision from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) on a Paediatric...
Protagonist Therapeutics announced topline results from the Phase 2 IDEAL study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).
Also Read: Glass Lewis Proxy...
BioVaxys Technology Corp., announced that it has entered into an agreement with the Deaconess Research Institute ("DRI") to supply BioVaxys with surgically debulked tumors...
AIkido Pharma Inc. reported that, on April 20, 2022, the independent Proxy Paper analysis firm Glass Lewis issued a report ("GL Report") providing an...
